Global Anti Microbial Peptides Market Report 2030: Based on Peptides Type, Based on Products, Based on Application & by Region with Forecast 2017-2030

Global Anti Microbial Peptides Market Overview

In 2013, as per US Centers for Disease Control and Prevention, over 2 million health related problems were reported in the U.S., out of which 23,000 people died due to drug-resistant microbes. In 2012, in the U.S., more than 450,000 new cases were registered against multidrug resistant tuberculosis. Rising number drug resistant cases across the world is creating need for the development of new antibiotics to fight against simple infectious diseases. Peptides such as Oxytocin, Cyclosporin, Salmon Calcitonin, Integrillin and Zoladex are widely accepted and are discovering new ways for peptide therapeutics market across the globe. As Anti-Microbial Peptides Market is in its embryonic stage and R&D is also facing challenges in developing new antimicrobials peptides. To prioritize the things U.S. and European Union government have taken initiatives and launched a Transatlantic Task Force and the Infectious Diseases Society of America in 2012 for the development of novel antimicrobial peptides by the end of 2020. Moreover, in Asia-Pacific region, Australian and New Zealand biotechnology organizations are funding together in manufacturing of new peptides. In 2007, Mimotopes Pty Ltd. and GlycoSyn were funded with USD 519.85 million to manufacture new peptides and specialized small molecules under the conditions of Good Manufacturing Practices (GMP).

Leading market players are collaborating to perform research on anti-microbial peptides. For instance, Symcel and Colzyx have partnered together to test antimicrobial peptides and their ability to restrict the bacterial growth. Recently established companies such as Nuritas are combining artificial intelligence and DNA analysis to find out peptides which can provide health benefits. Moreover, PFIZER acquired COVX to expand its bio-therapeutics investments for the identification of new peptide products.

Global Anti Microbial Peptides Market Segmentation

Global Anti-Microbial Peptides Market is categorized on the following basis:

• Based on Peptides Type
  • Plant Anti-Microbial Peptides
  • Bacterial Anti-Microbial Peptides
  • Animal Anti-Microbial Peptides
  • Insects Anti-Microbial Peptides
• Based on Products
  • Natural Anti-Microbial Peptides
  • Artificial Anti-Microbial Peptides
• Based on Application
  • Personal Care and Cosmetics Industry
  • Healthcare & Pharmaceuticals Industry
  • Biotechnology Industry
• Based on Geography
  • North America (U.S. & Canada) {Market Size (USD Billion), Growth Analysis (%) and Adoption Rate (%)}
  •  Latin America (Brazil, Mexico & Rest of Latin America)         {Market Size (USD Billion), Growth Analysis (%) and Adoption Rate (%)}
  • Europe (The U.K., Germany, France, Italy, Spain, Poland, Sweden & RoE) {Market Size (USD Billion), Growth Analysis (%) and Adoption Rate (%)}
  • Asia-Pacific (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Rest of Asia) {Market Size (USD Billion), Growth Analysis (%) and Adoption Rate (%)}
  • Middle East & Africa (GCC, South Africa, North Africa, RoMEA) {Market Size (USD Billion), Growth Analysis (%) and Adoption Rate (%)}
  •  Rest of World {Market Size (USD Billion), Growth Analysis (%) and Adoption Rate (%)}

Market Size and Forecast (2017-2030)

Peptide therapeutics market holds 2-3% of share in global pharmaceuticals market. The global antimicrobial peptide market is highly fragmented and valued USD 1.06 billion in 2015. The global market for antimicrobial peptide is anticipated to grow at a CAGR of 7.5% through the forecast period of 2017-2030.

Europe and North America are the leading regions for global anti-microbial peptide market due to large investment in R&D. Collectively Europe and North America held approximately 80% share of global antimicrobial peptides market in 2016. North America anti-microbial peptides market valued USD 0.44 billion in 2016. Presence of leading players in the region and huge of R&D spending is supporting the growth of anti-microbial peptides market in North America region.

Asia Pacific antimicrobial peptide market valued USD 0.18 billion in 2016 and is expected to showing a potential market growth in near future. Rising R&D investment to develop novel anti-microbial peptides in countries such as Australia, Japan, Singapore and South Korea is likely to contribute in the growth of anti-microbial peptides market in the region. However, Latin America and MEA together holds only 2-4% share of global antimicrobial peptides market due to lack of availability of medical amenities in the region.

Market Drivers and Challenges

Anti-microbial peptides have a promising growth as therapeutic agents to fight against problems mainly for skin infections. Anti-microbial peptides are an outstanding entrant for immune-modulatory activities and antifungal agents. Anti-microbial peptides help in improving anti-inflammatory cell response and also have an ability to disintegrate deadly cancerous cell membranes and considered as a potential drug for the treatment of cancer. Growing demand for the treatment of cancer, HIV and diabetes are likely to drive growth of anti-microbial peptides market in the near future.

High initial investment and manufacturing cost of peptides is required in early phase of research is a major challenge for research and development of anti-microbial peptides. Lack of financial support in research or peptide therapeutics for biotechnology and pharmaceutical industry is hindering the expansion of antimicrobial-peptide market globally. Moreover, anti-microbial peptides are currently is under clinical trials and stability of antimicrobial peptides in vivo environment and half life is still uncertain. These factors are limiting the growth of antimicrobial peptides market across the globe.

Covered in this Anti Microbial Peptides Market Report 

Market Synopsis

Market Segmentation

The Global Anti microbial peptides Market is segmented as follows:

• By Peptides Type (Market Size, Demand Analysis and Growth Analysis)

• By Products (Market Size, Demand Analysis and Growth Analysis)
• By Application (Market Size, Demand Analysis and Growth Analysis)

By Regions

• North America (U.S., Canada) {Market Size, Growth Analysis and Opportunity Analysis}

• Latin America (Argentina, Mexico, Brazil and Rest of Latin America) {Market Size, Growth Analysis and Opportunity Analysis}
• Europe (Germany, Italy, Spain, France, The U.K., Netherlands, Sweden, Hungary, Russia, Poland, Rest of Europe) {Market Size, Growth Analysis and Opportunity Analysis}
• Asia-Pacific (China, India, Singapore, Japan, Hong-Kong, Australia, New Zealand, South Korea and Rest of Asia Pacific) {Market Size, Growth Analysis and Opportunity Analysis}
• Middle East and North Africa (MENA) {Market Size, Growth Analysis and Opportunity Analysis}
• Rest of World  {Market Size, Growth Analysis and Opportunity Analysis}

Market Dynamics: Growth Drivers, Restraints and Opportunities

• Risk Factors

• Regional Variations
• Recent Trends and Developments

Key Market Players

• AnaSpec Inc.

• Synopsis
• Business Strategy
• Product Portfolio
• SWOT Analysis

• Chinese Peptides
• Novozymes
• Lonza
• Ipsen
• Bachem Holding AG
• Nuritas
• Dermagen
• Phoenix Biotech
• AMP Biotech
• Shanghai Abbiochem Company
• Ramamoorthy Group
• Lytix Biopharma AS
• Ai2 Ltd
• C3 Jian Therapeutics

Porter’s Five Force Model

Market Landscape: Competition and Beyond

Market outlook for business players and entry level players to ascertain their business in dynamic ecosystem

Expert Analysis

Concluding Remarks